Allied Market Research

2024

Argatroban Market

Argatroban Market Size, Share, Competitive Landscape and Trend Analysis Report by Product and by Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Argatroban is a thrombin inhibitor that prevents the clotting of blood. Its chemical name is 1-[5-[(aminoiminomethyl) amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl) sulfonyl] amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. It is used to treat conditions such as heparin-induced thrombocytopenia (HIT). Heparin is a more commonly used thrombin inhibitor, but it results in deficiency of blood platelet count in some cases. This has fueled the need for a heparin alternative. Argatroban caters to this need by acting as a thrombin inhibitor without leading to any heparin-like complications.

The global argatroban market is segmented based on product, application, and geography. On the basis of product, the market is bifurcated into argatroban powder and argatroban injection. Applications covered in this study include heparin-induced thrombocytopenia (hit), percutaneous coronary intervention, cerebral arterial thrombosis, and others. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The growth of the global argatroban market is driven by increase in the number of heparin-related complications among patients and rise in incidence of percutaneous coronary intervention procedures & cerebral arterial thrombosis. However, increase in allergies associated with argatroban is expected to hinder the market growth.

Comprehensive competitive analysis and profiles of major market players such as Pfizer, GlaxoSmithKline, SANDOZ, Eagle Pharmaceuticals, Fresenius Kabi, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, and WEST-WARD are provided in this report.

Key Benefits

  • This report offers a detailed quantitative analysis of the current market trends¬†to identify the prevailing opportunities.
  • The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
  • The global market is analyzed with respect to product type, application, and geography.
  • In-depth analysis based on geography facilitates to analyze the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Argatroban Market Report Highlights

Aspects Details
icon_5
By Product
  • Argatroban Powder
  • Argatroban Injection
icon_6
By Application
  • Heparin-induced Thrombocytopenia (HIT)
  • Percutaneous Coronary Intervention
  • Cerebral Arterial Thrombosis
  • Others
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_8
Key Market Players

AUROBINDO PHARMA LIMITED, MIDAS PHARMA GMBH, WEST-WARD, Fresenius Kabi, Pfizer, Eagle Pharmaceuticals, Teva Pharmaceutical Industries, SANDOZ, GlaxoSmithKline, Mitsubishi Tanabe Pharma

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Argatroban Market

Global Opportunity Analysis and Industry Forecast, 2023-2032